Rosaprostol is an antiulcer drug. This compound acts on the mucosal barrier in the stomach, preventing a drop in pH. More specifically, rosaprostol exhibits gastric antisecretory activity and cytoprotective action. Importantly, it does not have the undesired side effects (such as diarrhea and uterine stimulation) of other prostanoids. Rosaprostol was found to antagonize gastric acid output induced by NSAID administration and to prevent and treat the digestive disorders that resulted from taking NSAIDs. Furthermore, symptoms in patients with gastritis disappeared after administration of rosaprostol, and the drug was well-tolerated. Positive effects of rosaprostol were also reported in patients with duodenal ulcer. Several stereoisomers of rosaprostol have been synthesized.

Nofecainide (RP 30356, nofedone) is a Class I antiarrhythmic agent. RP 30356 blocked the action potential of frog atrial fibres without noticeably altering the resting membrane potential. RP 30356 inhibited the fast sodium conductance without changing the selectivity of the Na channel. The time to peak of the inward current was not significantly altered by the drug whereas the rate of the Na current inactivation pi h was slowed. The steady state inactivation membrane potential relationship of the Na system was shifted toward negative membrane potentials by the drug. The inhibition of the Na conductance by RP 30356 was frequency-dependent. RP 30356 might be effective in the control of cardiac arrhythmias since it mainly decreased the excitability of depolarized fibres.

Nixylic acid, an anilinonicotinic acid derivative, is an anti-inflammatory agent.

Delanterone is an antiandrogen steroid, developed by the Dutch company Gist-Brocades N.V. for the treatment of various dermatological disorders, including hirsutism, acne, seborrhea, alopecia androgenetica, and baldness. The compound is claimed to show topical anti-androgenic activity with very weak systemic anti-androgenic activity, a lack of progesterone, anti-gonadotrophin and corticosteroid-like activity and very low toxicity.

Lobeglitazone (trade name Duvie; Chong Kun Dang Pharmaceutical Corporation) was developed as effective and safe antidiabetic TZD drug. Lobeglitazone is a peroxisome proliferator-activated receptor-γ agonist. Lobeglitazone was conceptually designed by modification of the rosiglitazone structure with a substituted pyrimidine. Lobeglitazone has a p-methoxyphenoxy group at the 4-position of the pyrimidine moiety. Lobeglitazone showed more potent activity than the reference compounds (pioglitazone and rosiglitazone) with an EC50 value of 0.018 uM in a type 2 diabetes animal model, which is 16 times lower than pioglitazone (EC50 0.30 uM). Lobeglitazone exhibited similar efficacy profiles in glycemic control and lipid modulation to pioglitazone, but with a 30 times smaller dose in clinical studies. Lobeglitazone displays 12 times higher affinity to PPARγ than rosiglitazone and pioglitazone. Lobeglitazone acts as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By promoting the binding of insulin at fat cells, lobeglitazone has been shown to reduce blood sugar levels, lower hemoglobain A1C (HbA1C) levels, and improve lipid and liver profiles. Lobeglitazone was approved by the Ministry of Food and Drug Safety (Korea) in 2013. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.

Nebidrazine (FLA-136) is a selective agonist at central alpha-adrenoreceptors mediating changes in the turnover of noradrenaline. Nebidrazine is a sedative agent.

Darsidomine sydnonimine derivative, which serves as NO donor. Administration of darsidomine causes selective dilation of the coronary artery. The drug has an anti-ischemic action without inducing tolerance on long-term administration.

Cyclomenol is a bactericide compound, discovered at Institute Francais Du Petrole.